A practical reference on Albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-13. Anything still debated is marked as such rather than presented as settled.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
=== Very long-chain acyl-Coenzyme A dehydrogenase (VLCAD) deficiency === Very long-chain acyl-coenzyme A dehydrogenase deficiency (VLCAD deficiency) is a genetic disorder that affects the body's ability to break down certain fats. In the β-oxidation cycle, VLCAD's role involves the removal of two hydrogen atoms from the acyl-CoA molecule, forming a double bond and converting it into trans-2-enoyl-CoA. This crucial first step in the cycle is essential for the fatty acid to undergo further processing and energy production. When there is a deficiency in VLCAD, the body struggles to effectively break down long-chain fatty acids. This can lead to a buildup of these fats and a shortage of energy, particularly during periods of fasting or increased physical activity. Symptoms
==== Checks and balances ==== In March 2025 Larson showed visible frustration at Elon Musk's failure to appear before the House Ways and Means Committee and answer DOGE data transparency questions. On April 6, 2026, Larson filed articles of impeachment against President Donald Trump.
==== 1.A α-type channels ==== 1.A.1 Voltage-gated ion channel superfamily 1.A.2 Inward-rectifier K+ channel family 1.A.3 Ryanodine-inositol-1,4,5-trisphosphate receptor Ca2+ channel family 1.A.4 Transient receptor potential Ca2+ channel family 1.A.5 Polycystin cation channel family 1.A.6 Epithelial Na+ channel family 1.A.7 ATP-gated P2X receptor cation channel family 1.A.8 Major intrinsic protein superfamily 1.A.9 Neurotransmitter receptor, Cys loop, ligand-gated ion channel family 1.A.10 Glutamate-gated ion channel family of neurotransmitter receptors 1.A.11 Ammonium channel transporter family 1.A.12 Intracellular chloride channel family 1.A.13 Epithelial chloride channel family 1.A.14 Testis-enhanced gene transfer family 1.A.15 Nonselective cation channel-2 family 1.A.16 Formate-nitrite transporter family 1.A.17 Calcium-dependent chloride channel family 1.A.18 Chloroplast envelope anion-channel-forming Tic110 family 1.A.19 Type A influenza virus matrix-2 channel family 1.A.20 BCL2/Adenovirus E1B-interacting protein 3 family 1.A.21 Bcl-2 family 1.A.22 Large-conductance mechanosensitive ion channel 1.A.23 Small-conductance mechanosensitive ion channel 1.A.24 Gap-junction-forming connexin family 1.A.25 Gap-junction-forming innexin family 1.A.26 Mg2+ transporter-E family 1.A.27 Phospholemman family 1.A.28 Urea transporter family 1.A.29 Urea/amide channel family 1.A.30 H+- or Na+-translocating bacterial MotAB flagellar motor/ExbBD outer-membrane transport energizer superfamily 1.A.31 Annexin family 1.A.32 Type B influenza virus NB channel family 1.A.33 Cation-channel-forming heat shock protein 70 family 1.A.34 Bacillus gap junction-like channel-forming complex family 1.A.35 CorA metal ion transporter family 1.A.36 Intracellular chloride channel family 1.A.37 CD20 Ca2+ channel family 1.A.38 Golgi pH regulator family 1.A.39 Type C influenza virus CM2 channel family 1.A.40 Human immunodeficiency virus type I Vpu channel family 1.A.41 Avian reovirus p10 Vvroporin family 1.A.42 HIV viral protein R family 1.A.43 Camphor resistance or fluoride exporter family 1.A.44 Pore-forming tail Tip pb2 protein of phage T5 family 1.A.45 Phage P22 injectisome family 1.A.46 Anion channel-forming bestrophin family 1.A.47 Nucleotide-sensitive anion-selective channel, ICln family 1.A.48 Anion channel Tweety family 1.A.49 Human coronavirus ns12.9 viroporin family 1.A.50 Phospholamban (Ca2+-channel and Ca2+-ATPase regulator) family 1.A.51 The Voltage-gated Proton Channel (VPC) Family 1.A.52 The Ca2+ Release-activated Ca2+ (CRAC) Channel (CRAC-C) Family 1.A.53 The Hepatitis C Virus P7 Viroporin Cation-selective Channel (HCV-P7) Family 1.A.54 The Presenilin ER Ca2+ Leak Channel (Presenilin) Family 1.A.55 The Synaptic Vesicle-Associated Ca2+ Channel, Flower (Flower) Family 1.A.56 The Copper Transporter (Ctr) Family 1.A.57 The Human SARS Coronavirus Viroporin (SARS-VP) 1.A.58 The Type B Influenza Virus Matrix Protein 2 (BM2-C) Family 1.A.59 The Bursal Disease Virus Pore-Forming Peptide, Pep46 (Pep46) Family 1.A.60 The Mammalian Reovirus Pre-forming Peptide, Mu-1 (Mu-1) Family 1.A.61 The Insect Nodavirus Channel-forming Chain F (Gamma-Peptide) Family 1.A.62 The Homotrimeric Cation Channel (TRIC) Family 1.A.63 The Ignicoccus Outer Membrane α-helical Porin (I-OMP Family 1.A.64 The Plasmolipin (Plasmolipin) Family 1.A.65 The Coronavirus Viroporin E Protein (Viroporin E) Family 1.A.66 The Pardaxin (Pardaxin) Family 1.A.67 The Membrane Mg2+ Transporter (MMgT) Family 1.A.68 The Viral Small Hydrophobic Viroporin (V-SH) Family 1.A.69 The Heteromeric Odorant Receptor Channel (HORC) Family 1.A.70 The Molecule Against Microbes A (MamA) Family 1.A.71 The Brain Acid-soluble Protein Channel (BASP1 Channel) Family 1.A.72 The Mer Superfamily 1.A.73 The Colicin Lysis Protein (CLP) Family 1.A.74 The Mitsugumin 23 (MG23) Family 1.A.75 The Mechanical Nociceptor, Piezo (Piezo) Family 1.A.76 The Magnesium Transporter1 (MagT1) Family 1.A.77 The Mg2+/Ca2+ Uniporter (MCU) Family 1.A.78 The K+-selective Channel in Endosomes and Lysosomes (KEL) Family 1.A.79 The Cholesterol Uptake Protein (ChUP) or Double Stranded RNA Uptake Family 1.A.80 The NS4a Viroporin (NS4a) Family 1.A.81 The Low Affinity Ca2+ Channel (LACC) Family 1.A.82 The Hair Cell Mechanotransduction Channel (HCMC) Family 1.A.83 The SV40 Virus Viroporin VP2 (SV40 VP2) Family 1.A.84 The Calcium Homeostasis Modulator Ca2+ Channel (CALHM-C) Family 1.A.85 The Poliovirus 2B Viroporin (2B Viroporin) Family 1.A.86 The Human Papilloma Virus type 16 (HPV16) L2 Viroporin (L2 Viroporin) Family 1.A.87 The Mechanosensitive Calcium Channel (MCA) Family 1.A.88 The Fungal Potassium Channel (F-Kch) Family 1.A.89 The Human Coronavirus 229E Viroporin (229E Viroporin) Family 1.A.90 The Human Metapneumovirus (HMPV) Viroporin (HMPV-Viroporin) Family 1.A.91 The Cytoadherence-linked Asexual Protein 3.2 of Plasmodium falciparum (Clag3) Family 1.A.92 The Reovirus Viroporin VP10 (RVP10) Family 1.A.93 The Bluetongue Virus Non-Structural Protein 3 Viroporin (NS3) Family 1.A.94 The Rotavirus Non-structural Glycoprotein 4 Viroporin (NSP4) Family 1.A.95 The Ephemerovirus Viroporin (EVVP) Family 1.A.96 The Human Polyoma Virus Viroporin (PVVP) Family 1.A.97 The Human Papillomavirus type 16 E5 Viroporin (HPV-E5) Family 1.A.98 Human T-Lymphotropic Virus 1 P13 protein (HTLV1-P13) Family 1.A.99 The Infectious Bronchitis Virus Envelope Small Membrane Protein E (IBV-E) Family 1.A.100 The Rhabdoviridae Putative Viroporin, U5 (RV-U5) Family 1.A.101 The Peroxisomal Pore-forming Pex11 (Pex11) Family 1.A.102 Influenza A viroporin PB1-F2 (PB1-F2) Family 1.A.103 The Simian Virus 5 (Parainfluenza Virus 5) SH (SV5-SH) Family 1.A.104 The Proposed Flagellar Biosynthesis Na+ Channel, FlaH (FlaH) Family 1.A.105 The Mixed Lineage Kinase Domain-like (MLKL) Family 1.A.106 The Calcium Load-activated Calcium Channel (CLAC) Family 1.A.107 The Pore-forming Globin (Globin) Family
5-oxoprolyl-peptide + H2O Hence, this enzyme has one substrate, L-glutaminyl-peptide or L-glutamyl-peptide, and two products, 5-oxoprolyl-peptide and NH3 or H2O. The N-terminal 5-oxoproline residue on the peptide is also commonly known as pyroglutamic acid. This enzyme belongs to the family of transferases, specifically the aminoacyltransferases. The systematic name of this enzyme class is L-glutaminyl-peptide gamma-glutamyltransferase (cyclizing). Other names in common use include glutaminyl-tRNA cyclotransferase, glutaminyl cyclase, and glutaminyl-transfer ribonucleate cyclotransferase.
Baker's yeast Bioaerosol Ethanol fermentation Evolution of aerobic fermentation Kazachstania yasuniensis – a yeast isolated in 2015 Mycosis (fungal infection in animals) Start point (yeast) WHI3 Yeast plasmids Zymology
Sources: en.wikipedia.org
∗Fifteen puffs were chosen to estimate the nicotine delivery of one traditional cigarette. Each e-cigarette cartridge, which varies across manufacturers, and each cartridge produces 10 to 250 puffs of vapor. This correlates to 5 to 30 traditional cigarettes. A puff usually lasts for 3 to 4 seconds. A 2014 study found there is wide differences in daily puffs in experienced vapers, which typically varies from 120 to 225 puffs per day. From puff-to-puff e-cigarettes do not provide as much nicotine as traditional cigarettes. A 2016 review found "The nicotine contained in the aerosol from 13 puffs of an e-cigarette in which the nicotine concentration of the liquid is 18 mg per milliliter has been estimated to be similar to the amount in the smoke of a typical tobacco cigarette, which contains approximately 0.5 mg of nicotine."
Myofibrillar myopathy 10, dimethylglycine dehydrogenase deficiency, erythrocyte lactate transporter defect, and myopathy with myalgia, increased serum creatine kinase, with or without episodic rhabdomyolysis (MMCKR) also include muscle fatigue. X-linked episodic muscle weakness (EMWX) includes general muscle weakness, ptosis, and fluctuations in strength. In some individuals, fatiguability was demonstrable, the phenotype having features comparable to congenital myasthenic syndromes and channelopathies. Signs and symptoms of myasthenia presenting from infancy or childhood may be one of the congenital myasthenic syndromes, which can be inherited in either an autosomal dominant or recessive manner. There are currently over two dozen types of congenital myasthenic syndromes. Limb–girdle myasthenia gravis is a distinct condition from myasthenia gravis. It is an adult-onset, autoimmune condition affecting the neuromuscular junction. However, it lacks eye abnormalities and is associated with autoimmune conditions such as systemic lupus erythematosus, Hashimoto's thyroiditis, and thymoma. Lambert–Eaton myasthenic syndrome (LEMS) is an autoimmune condition that attacks the neuromuscular junction, either as a paraneoplastic syndrome (typically older people) or associated with a non-cancerous primary autoimmune condition (typically younger people). It usually involves lower limb weakness and exercise-induced fatiguability, although the upper limbs and eyes may also be involved.
==== 600–699 ==== Appropriation (Northern Ireland) Order 1993 (S.I. 1993/600) Insurance (Fees) Regulations 1993 (S.I. 1993/601) Insolvency (Amendment) Rules 1993 (S.I. 1993/602) Civil Jurisdiction and Judgments Act 1982 (Amendment) Order 1993 (S.I. 1993/603) Civil Jurisdiction and Judgments (Authentic Instruments and Court Settlements) Order 1993 (S.I. 1993/604) Maximum Number of Judges Order 1993 (S.I. 1993/605) Maximum Number of Judges (Northern Ireland) Order 1993 (S.I. 1993/606) Air Navigation (Fourth Amendment) Order 1993 (S.I. 1993/607) National Health Service (Travelling Expenses and Remission of Charges) Amendment Regulations 1993 (S.I. 1993/608) Further Education (Attribution of Surpluses and Deficits) Regulations 1993 (S.I. 1993/609) Veterinary Surgeons and Veterinary Practitioners (Registration) (Amendment) Regulations Order of Council 1993 (S.I. 1993/610) Education (Welsh Agricultural College Higher Education Corporation) (Designated Staff) Order 1993 (S.I. 1993/611) Education (Further Education Corporations) (Designated Staff) (Wales) Order 1993 (S.I. 1993/612) Local Government Finance (Payments) (Welsh Authorities) Regulations 1993 (S.I. 1993/613) National Board for Nursing, Midwifery and Health Visiting for Wales (Constitution and Administration) Order 1993 (S.I. 1993/614) Valuation and Community Charge Tribunals (Amendment) (No. 2) Regulations 1993 (S.I. 1993/615) Local Government Finance (Repeals, Savings and Consequential Amendments) Order 1993 (S.I.
Amanita virosa is highly toxic, and has been responsible for severe mushroom poisonings. Eating just one cap of A. virosa is enough to kill an adult human. The symptoms of poisoning generally come several hours after consumption, a delay which may make treatment more difficult. Fruit bodies contain both amatoxins and phallotoxins. Amatoxins consist of at least eight compounds with a similar structure, that of eight amino-acid rings; they were isolated in 1941 by Heinrich O. Wieland and Rudolf Hallermayer of LMU Munich. Of the amatoxins, α-Amanitin is the chief component and along with β-Amanitin is probably responsible for the toxic effects. Their major toxic mechanism is the inhibition of RNA polymerase II, a vital enzyme in the synthesis of messenger RNA (mRNA), microRNA, and small nuclear RNA, (snRNA). Without mRNA essential protein synthesis and hence cell metabolism cease and the cell dies. The liver is the principal organ affected, as it is the organ which is first encountered after absorption in the gastrointestinal tract, though other organs, especially the kidneys, are susceptible. Phallotoxins consist of at least seven compounds, all of which have seven similar peptide rings. Phalloidin was isolated in 1937 by Feodor Lynen, Heinrich Wieland's student and son-in-law, and Ulrich Wieland of LMU Munich. Though phallotoxins are highly toxic to liver cells, they have since been found to have little input into the destroying angel's toxicity as they are not absorbed through the gut. Furthermore, phalloidin is also found in the edible Amanita rubescens.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.